Jump to content

Pharmion Begins Late Stage Study Of Amrubicin for SCLC


Recommended Posts

10/17/2007 10:05:43 AM Pharmion Corp. (PHRM) announced that it has begun an international pivotal Phase 3 clinical trial evaluating amrubicin, the company's third-generation synthetic anthracycline, in the treatment of second-line small cell lung cancer or SCLC.

The randomized, controlled, multi-center study will compare amrubicin to topotecan, the only approved chemotherapy for second-line treatment of SCLC in the US and EU. Enrollment in the study of 480 patients is underway.

Approximately 30,000 patients in the US and 32,000 patients in the EU will be diagnosed with SCLC this year.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.